URTY
Market cap | $30.41 Million |
---|---|
Enterprise Value | $-170,959,008.00 |
Dividend Yield | $0.60 (1.23%) |
Earnings per Share | $- |
Beta | 3.59 |
Outstanding Shares | - |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | - |
---|---|
PEG | - |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | -9.35 |
Enterprise Value to EBIT | 6.26 |
Enterprise Value to Net Income | 5 |
Total Debt to Enterprise | -0.11 |
Debt to Equity | 0.06 |
No data
No data
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...